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Introduction
The immune contexture is widely recognized as an important determinant of overall survival in cancer patients 1 . In particular, the presence of cytotoxic CD8 + T cells at high density within tumor tissue is beneficial in multiple cancer types including colorectal, ovarian, and melanoma, and can be a better prognostic indicator of patient outcome than traditional tumor-node-metastasis (TMN) staging [1] [2] [3] [4] [5] [6] . Active areas of research seek to improve T cellmediated immunity in patients by focusing on therapeutics that manipulate either the T cell arm of antitumor immunity or the tumor microenvironment where T cells execute their effector functions [7] [8] [9] . The frequency of tumor-specific T cells and their cytotoxic function can be boosted through DC vaccination, adoptive T cell transfer (ACT) therapy, or administration of checkpoint blockade inhibitors (e.g., targeting immunosuppressive molecules such as cytotoxic T-lymphocyte-associated protein 4 or programmeddeath/programmed-death ligand 1 [PD-1/PD-L1]) and has led to durable responses in a subset of patients 8, [10] [11] [12] [13] . Alternatively, we and others have converted the tumor microenvironment from relatively 'low' to 'high' sites of T cell infiltration in preclinical studies using TLR agonists, IFNs, antagonists of endothelin B and angiogenic factors, or interleukin-6 (IL-6)-dependent strategies 9, [14] [15] [16] [17] . Fundamental to the efficacy of all T cellbased immunotherapy is the requirement for blood-borne T cells to gain entry across tumor vascular gateways in order to engage in contact-dependent lysis of neoplastic targets.
Given the importance of intratumoral localization of T cells for antitumor immunity, there is surprisingly little known about the trafficking cues necessary to direct extravasation of effector T cells across tumor vessels. Chemokines are considered strong candidates for this process based on their well-established role in T cell trafficking to lymphoid organs 18 . In lymph nodes, for example, the interaction between G αi -protein-coupled chemokine receptors (e.g., CCR7) on naïve T cells and chemokine (CCL21) displayed on the lumenal surface of blood vessels is an obligate step for triggering LFA-1-dependent stable adhesion and subsequent transendothelial migration 18, 19 . Insight into the role of chemokines in the tumor microenvironment stems from correlative studies linking T cell accumulation with multiple chemokine receptors on effector T cells and/or chemokines within the tumor locale 1, 20, 21 . In this regard, expression of CXCR3 on circulating T cells or its chemokine ligands, CXCL9 and CXCL10, in tumor tissues is associated with elevated intratumoral T cell infiltration and a favorable outcome in melanoma and colorectal cancer patients 1, [20] [21] [22] . Similar clinical evidence connects CCR5 and its ligands (CCL3, CCL4, and CCL5), as well as CCR2 and its ligand CCL2, to intratumoral T cell infiltration and disease-free survival 1, 20, 21 . These observations are suggestive of redundant functions by chemokine receptors during T cell homing into tumors although chemokines could alternatively orchestrate T cell activities within the tumor interstitium (e.g., proliferation, survival, retention, or egress) 19 . Moreover, the prototypical role for chemokines has recently been challenged by reports in nontumorigenic inflammatory settings that CD8 + effector T cells with high LFA-1 expression bypass chemokine requirements for stable adhesion within vessels 23, 24 . Thus, in the absence of a head-to-head comparison of the chemokine receptor usage at the tumor vascular interface, it remains unclear whether chemokines are operative during T cell entry into tumors or if there is any preferential role for individual chemokine receptors/chemokine pairs during extravasation.
Here, we investigated the hierarchy of chemokine receptor requirements during T cell trafficking by tracking the fate of adoptively transferred CD8 + effector T cells in murine and human melanoma tumors. We compared the functions of three chemokine receptors previously implicated in intratumoral CD8 + effector T cell infiltration (i.e., CXCR3, CCR5, and CCR2) in tumors expressing complementary chemokine ligands. These studies unexpectedly reveal a non-redundant requirement for the CXCR3-CXCL9/CXCL10 axis for CD8 + T cell trafficking within the intravascular space that could not be predicted from static profiling of intratumoral chemokines or their receptors on T cells. We further establish a causal link between CXCR3-dependent trafficking and the efficacy of adoptive T cell transfer therapy. These findings identify CXCR3 interactions with cognate chemokines within the vessel wall as a critical checkpoint dictating the efficacy of T cell-based cancer immunotherapy.
Results

Tumor microenvironment enriched for T cell chemoattractants
To address the chemokine receptor requirements during T cell homing, we first characterized the chemokine milieu in highly aggressive, orthotopic B16 murine melanoma expressing the surrogate tumor antigen ovalbumin (OVA) 14 . For these studies, we focused on inflammatory chemokines previously implicated in T cell infiltration in patient tumors 1, 3, 9, 20 . High concentrations (~1 ng per mg total protein) of CXCL9, CXCL10 (i.e., the two CXCR3 ligands expressed in the C57BL/6 strain 25 ), CCL5 (CCR5 ligand), and CCL2 (CCR2 ligand) were detected in B16-OVA tumor extracts compared to non-inflamed normal skin following subcutaneous injection of PBS (Fig. 1a) .
Complementary studies profiled CD8 + effector T cells for functional receptors specific for the inflammatory chemokines found in the tumor microenvironment. Chemotactic activity was tested in vitro for CD8 + T cells from OVA-specific OT-I transgenic mice [wild-type (WT)] or chemokine receptor-deficient mice that were activated ex vivo to simulate the expansion of T cells for clinical ACT immunotherapy 12, 14, 26 . WT OT-I effector populations (>96% CD8 + CD44 hi , Supplementary Fig. 1a ) exhibited strong migration to recombinant CXCL9, CXCL10, CCL5, and CCL2, that was blocked by pertussis toxin (PTX), a global inhibitor of G αi protein-coupled chemokine receptor signaling (Fig. 1b) . Genetic deletion of Cxcr3 (crossed on an OT-I background; Cxcr3 −/− OT-I) or Ccr5 and Ccr2 (on a C57BL/6 background) was further shown to specifically block T cell migration to its cognate ligands without impairing the response to other ligands (Fig. 1b) . CD8 + CD44 hi T cells activated ex vivo exhibited a CXCR3 hi CCR2 int/lo CCR5 int/lo phenotype which was also typical of CD8 + T cells activated in vivo (i.e., detected in draining nodes following DC vaccination or tumor implantation; Supplementary Fig. 1b) . Collectively, these data indicate that CD8 + effector T cells express a repertoire of functional chemokine receptors which would be expected to guide trafficking to chemokine-rich tumors in situ.
CXCR3 signaling obligate for intratumoral T cell trafficking
Short-term (1 hour) competitive homing assays were used 14, 27 to determine whether G αi -chemokine signaling was obligatory for T cell trafficking in B16-OVA. In these assays, WT effector OT-I cells were admixed at a 1:1 ratio with PTX-pretreated WT OT-I T cells (labeled with different tracking dyes) prior to intravenous ACT (Fig. 2a) . After 1 hour, the ratio of T cells was determined in tumor tissues by flow cytometry, and data are reported for homing relative to untreated WT OT-I cells. This 1 hour time-frame enabled us to discriminate chemokine functions specifically at the vessel wall since it is sufficient for cells to complete steps leading to extravasation 14 , but not long enough for other processes to occur that influence the extent of T cell infiltration (i.e., proliferation in situ, survival, retention and egress). Homing of PTX-treated OT-I was less efficient than WT OT-I, as indicated by the 1:3 ratio of PTX:WT cells recovered in tumors (Fig. 2b) . This was in contrast to control experiments where a 1:1 ratio of intratumoral WT:WT cells was detected. Access of effector T cells to the spleen via the peripheral circulation was not affected by functional chemokine receptor status (Fig. 2b) . These data establish that G αi -coupled chemokine receptor signaling is necessary for effector CD8 + T cell homing in tumors.
We next investigated whether there was a hierarchy of chemokine receptor usage during extravasation into tumor tissue. Initial studies focused on CXCR3 requirements for the entry of adoptively transferred effector T cells in competitive (1 hour) homing assays in which WT OT-I cells were admixed with Cxcr3 −/− OT-I T cells or with OT-I cells pre-treated with a CXCR3-blocking antibody (Ab). Surprisingly, despite expression of functional CCR5 and CCR2 (Fig. 1b) , loss of the single chemokine receptor, CXCR3, reduced T cell trafficking to the same extent as global blockade of chemokine signaling by PTX (Fig. 2b) . Further headto-head comparison of admixed PTX-pretreated and Cxcr3 −/− OT-I cells in the same recipient mice substantiated that CXCR3 accounted for all G αi -coupled chemokine receptordependent trafficking by CD8 + effectors in B16-OVA melanoma ( Supplementary Fig. 2a ). Microscopic quantification of homed cells within the interstitium (i.e., T cells located outside CD31 + vessels in tumor sections) further demonstrated an absolute requirement for CXCR3 during T cell extravasation (Fig. 2c) . Contributions of other chemokine receptors failed to emerge even when the overall rate of trafficking was improved (~2 fold) using an IL-6-dependent thermal preconditioning strategy (core body temperature elevated to 39.5 ± 0.5°C, 6 h) that targets the tumor vasculature to be more permissive for T cell homing 14 ( Fig. 2d and Supplementary Fig. 2b ). CXCR3 dependency was also evident during endogenous CD8 + T cell infiltration in tumors implanted in WT mice and Cxcr3-deficient mice ( Supplementary Fig. 2c ), suggesting that the same CXCR3 bias exists whether T cells are activated ex vivo or in vivo. Collectively, these data establish a non-redundant role for CXCR3-mediated G αi protein signaling during emigration of blood-borne CD8 + effector T cells in the tumor microenvironment.
CXCR3 ligands mediate T cell firm arrest in tumor vessels
Our findings demonstrated that CXCR3 is required at some point during the multistep migration process leading to CD8 + effector T cell migration. These observations prompted our use of epifluorescence intravital microscopy to examine whether CXCR3 plays a prototypical role in triggering T cell adhesion 18, 19 within the intravascular space in tumor tissues. Since our prior studies established that the frequency of baseline adhesive interactions between effector T cell and tumor vessels is near the lower limit of detection by live imaging 14 , we administered thermal therapy to augment homing in order to interrogate subtle chemokine requirements. PTX-uncoupling of G αi protein signaling or genetic deletion of Cxcr3 had no impact on the ability of OT-I cells to initiate rolling interactions within tumor vessels but strongly inhibited the transition to firm arrest (Fig. 3a) . Notably, WT and Cxcr3 −/− effector OT-I expressed comparable levels of adhesion molecules necessary for rolling and firm arrest (i.e., E/P-selectin ligands and CD11a [the α subunit of LFA-1], respectively; Supplementary Fig. 3a) . The dependence on G αi protein signaling further was not unique to tumor vessels since PTX-pretreated OT-I effectors exhibited significantly reduced firm arrest of CD8 + effectors in inflamed skin vessels of non-tumor-bearing mice stimulated with the TLR4 agonist, LPS ( Supplementary Fig. 3b ).
To determine if there was a preferential contribution for individual CXCR3 ligands for trafficking, we adapted an approach described previously to visualize membrane-anchored adhesion molecules in lymph node vasculature 28 in order to determine which CXCR3 ligands were available in the intravascular space. In the present study, intravascular chemokines were quantified microscopically in tissue sections following intravenous injection of fluorescent beads conjugated with CXCR3 ligand-specific Ab. These studies focused on CXCL9 and CXCL10 since C57BL/6 mice do not express CXCL11 25, 29 . Both CXCL9 and CXCL10 were displayed within tumor vessel walls as indicated by specific accumulation of α-CXCL10 and α-CXCL9 Ab-conjugated beads in CD31 + vessels compared to isotype controls (Fig. 3b) , whereas CXCR3 ligand-conjugated beads were not evident in normal tissues (e.g., pancreas). We then employed a chemokine blocking strategy in which tumor-bearing mice were pre-treated with blocking Ab to CXCL9, CXCL10, or combined CXCL9/CXCL10 25, 30 prior to adoptive transfer of admixed WT:Cxcr3 −/− T cells (Fig. 3c) . Partial inhibition of CD8 + T cell homing was observed with single chemokine blockade whereas complete inhibition occurred upon dual targeting of CXCL9 and CXCL10 (i.e., as indicated by 1:1 ratio of WT:Cxcr3 −/− cells recovered at tumor sites following dual Ab blockade which was equivalent to the input ratio; Fig. 3c ). There was no change in the spleen, confirming that the inhibitory effects on intratumoral homing cannot be attributed to Ab-mediated T cell clearance. Taken together, these data identify CXCR3 interactions with intravascular ligands as a critical step leading to stable adhesion and subsequent transendothelial migration of adoptively transferred CD8 + effector T cells at tumor sites.
CCR5 and CCR2 are dispensable for T cell homing to tumors
Results that CCR5 and CCR2 were unable to compensate for loss of CXCR3 in vivo do not exclude the possibility that these chemokine receptors cooperate with CXCR3 to control adhesion in tumor vessels. There is already precedent for cooperativity involving these chemokine receptors 31, 32 . For example, physical interactions between CCR5 and CXCR4 are required for CXCR4-mediated enhancement of T cell activation in vitro 32 while simultaneous exposure of cells to CCL2 and CCL5 lowers the threshold for downstream calcium mobilization 31 .
To assess whether CCR5 or CCR2 were operative in the context of CXCR3-dependent T cell trafficking, we first established that CCL5 and CCL2 were also available in the tumor intravascular space, as would be necessary to coordinate with CXCR3 ligands during extravasation (Fig. 4a) . We then performed competitive homing studies to examine the ability of Cxcr3 −/− , Ccr5 −/− , or Ccr2 −/− CD8 + effector CD8 + T cells to traffic compared to WT (Fig. 4b) . In these experiments the T cells used to track homing were from normal C57BL/6 mice, not the OT-I background. Consistent with our results for OT-I cells, trafficking was markedly inhibited by PTX-treatment of WT cells or Cxcr3 deficiency, indicating that recognition of cognate tumor-associated antigen is not necessary for CXCR3-dependent T cell extravasation at tumor loci. Conversely, loss of Ccr2 or Ccr5 did not compromise T cell entry into B16-OVA tumors or in peripheral sites such as the spleen (Fig.  4b ). Of note, while CCR2 did not contribute to T cell trafficking, there was sufficient ligand available to support CCR2-dependent intratumoral recruitment of CD115 + inflammatory monocytes 33 that have high CCR2 expression relative to CD8 + effectors ( Fig. 4c and 4d ; Supplementary Fig. 4 ). Since CCL2 and CCL5 have been implicated in T cell diapedesis in vitro 23 , we also considered whether Ccr5 −/− and Ccr2 −/− T cells were defective in their ability to migrate through tumor vessel walls which would not be discernible by flow cytometric analysis. Microscopic analysis did not reveal a disproportionate accumulation of adoptively transferred Ccr5 −/− or Ccr2 −/− T cells within tumor vessels nor a concomitant defect in extravasation (Fig. 4e) . Overall, these data demonstrate that CCR5 and CCR2 are not required to cooperate with CXCR3 during T cell extravasation across tumor vessels.
Efficacy of adoptive transfer cell therapy depends on CXCR3
Evidence that CXCR3 directs homing of adoptively transferred CD8 + T cells at the tumor vascular interface prompted us to investigate the relationship between CXCR3 and antitumor immunity. In these studies we initially characterized the cytotoxic activity of WT and Cxcr3 −/− OT-I T cells in assays where effectors have ready access to cognate targets. Activated Cxcr3 −/− and WT OT-I cells were indistinguishable with respect to IFN-γ and granzyme B expression ( Supplementary Fig. 5a ) and exhibit equivalent specific cytotoxicity against cognate targets in vitro including splenocytes pulsed with SIINFEKL OVA peptide, B16-OVA, or OVA-expressing EG7 lymphoma ( Supplementary Fig. 5b-d) . Parallel results were obtained during in vivo cytotoxicity assays against SIINFEKL-pulsed splenocyte targets within the splenic compartment (Fig. 5a ). These findings are in line with evidence that CXCR3 deficiency does not compromise localization of adoptively transferred CD8 + T cells within the spleen (Fig. 2b) .
To test the cytotoxic activity of T cells in tumors where entry depends on CXCR3, we adoptively transferred a single dose of WT or Cxcr3 −/− OT-I effector T cells intravenously into mice and monitored B16-OVA tumor progression. These studies exploited the OT-I TcR transgenic model system in order to dissect the therapeutic impact of chemokinedependent trafficking without masking chemokine contributions due to weak TCR affinity/ avidity for tumor antigen. WT OT-I T cells caused a significant delay in tumor growth and prolonged survival, with cures detected in some experiments (Fig. 5b, Supplementary Fig.  6a ). Conversely, CD8 + effectors lacking Cxcr3 provided no therapeutic benefit, compared to untreated controls, in this stringent model where 100% of transferred cells were tumor (OVA)-reactive. Kinetic studies performed after adoptive transfer showed a progressive increase in the extent of intratumoral infiltration by WT OT-I cells, but not Cxcr3 −/− OT-I (monitored using tracking dye or CD45 congenic mismatch), underscoring the CXCR3 requirements for tumor immunity (Fig. 5c, Supplementary Fig. 6b ). Additionally, we found that a high intratumoral density of WT OT-I (~10,000 OT-I per 10 6 total cells within tumors) correlated directly with tumor control in the majority of mice analyzed at 3 weeks post-adoptive transfer (i.e., tumors < 20 mm 3 in 9/12 mice) (Fig. 5d) . Conversely, WT OT-I were present at a low density (~50 OT-I/10 6 total cells in tumors) in the subgroup of mice in which tumors were progressing (tumors >450 mm 3 in 3/12 mice). Notably, the tumor volume and density of WT OT-I cells detected in progressing tumors was indistinguishable from observations in 100% of mice treated with Cxcr3 −/− OT-I that failed to reject tumors ( Fig. 5d ). These results are consistent with a prior report showing that OT-I must exceed a critical threshold within B16-OVA tumors for ACT immunotherapy to be successful 34 . Collectively, these data indicate that CXCR3-dependent signaling at the tumor vascular barrier is a critical checkpoint for the efficacy of adoptively transferred T cells.
Human effector T cells require CXCR3 for homing in melanoma
In light of the importance of CXCR3-dependent trafficking for antitumor immunity following adoptive T cell transfer therapy in mice, we extended our analysis of chemokine requirements to the trafficking of human effector T cells to human melanoma xenografts comprised of the M537 and M888 patient-derived melanoma cell lines 20, 35, 36 . We initially profiled chemokine receptor expression by human T cells that were activated and expanded ex vivo using clinical ACT protocols for cancer patients 12, 26, 37 . Activated PBL populations from normal donors (n=7) were predominantly CD3 + (>97%) with robust CXCR3 expression on CD8 + cells (i.e., the major T cell subset), while CCR2 and CCR5 were highly variable among individual donors as reported previously 20, 37, 38 (Fig. 6a, Supplementary Fig.  7a ). Chemotaxis assays in vitro further validated that activated human T cells expressed functional CXCR3, CCR5, and CCR2 which responded to both human and murine chemokines ( Supplementary Fig. 7b ). Since our studies with murine CD8 + effector T cells raised the possibility that limited CCR2 or CCR5 expression might be responsible for the failure to detect CCR2-or CCR5-dependent trafficking to murine melanoma, we selected representative donor T cell populations for adoptive transfer experiments that dually expressed high CXCR3/CCR2 (donor 1) or high CXCR3/CCR5 (donor 2) (Fig. 6a) .
To survey the chemokine milieu available to adoptively transferred T cells in human melanoma xenografts, we measured both tumor-derived (human) and stromal-derived (murine) chemokines produced in the local tumor milieu. Differential production of tumorderived (human) CXCL9, CXCL10, CXCL11, CCL2, and CCL5 was observed in M537 and M888 xenografts in vivo (Fig. 6b) which is largely in line with previous in vitro observations 20 . However, stromal-derived murine chemokines represented the vast majority of local chemokine and were detected at similar levels in M537 and M888 tumor extracts (Fig. 6b) . Thus, M537 and M888 tumors had similar chemokine microenvironments when considering the combined contributions from both mouse and human chemokines, allowing for chemokine-dependent trafficking to be investigated in both tumor systems.
Short-term competitive homing assays were then used to examine CXCR3 contributions during human T cell trafficking to melanoma xenografts (Fig. 6c) . CXCR3 activity was specifically disrupted on activated PBL prior to adoptive transfer with a blocking Ab that reportedly inhibits CXCR3-mediated migration in vitro 39 . As a second method, we desensitized T cells with recombinant CXCL10 to downregulate surface expression of CXCR3 40 . CXCR3 inactivation by these approaches was confirmed by flow cytometry or in vitro chemotaxis assays (Supplementary Fig. 7c ). Data in Fig. 6c demonstrate that loss of CXCR3 activity by Ab blockade or desensitization diminished homing of T cells from both donor 1 and donor 2 in M537 and M888 melanoma xenografts to the same extent as PTXpretreatment but did not alter localization in the spleen (Fig. 6c, Supplementary Fig. 8a ). Homed cell populations in tumors were ≥65% CD8 + T cells, which were reflective of the predominantly CD8 + T cell input population (Fig. 6a) . Thus, high expression of CCR2 or CCR5 by human effector T cells could not compensate for the absence of CXCR3. The CXCR3 requirement for trafficking in M537 and M888 was further validated in competitive homing assays using murine WT and Cxcr3 −/− CD8 + effector T cells ( Supplementary Fig.  9a,b) . Taken together, these data unequivocally show a non-redundant role for CXCR3 in trafficking of CD8 + human effector T cells in melanoma during adoptive T cell transfer immunotherapy.
Discussion
Successful delivery of blood-borne CD8 + effector T cells across the tumor vasculature is recognized as a key determinant of antitumor immunity. However, to date, there is no information about the hierarchy of chemokine receptors that guide tumoricidal T cells into the tumor microenvironment. Here, we report on the non-redundant function of CXCR3 and its complementary intravascular ligands during CD8 + T cell trafficking to tumor tissues. The requirement for CXCR3 is shared by both murine and human CD8 + effector T cells and is necessary for the efficacy of adoptive T cell transfer therapy in the B16-OVA tumor model. These findings provide mechanistic insight for observations in cancer patients that CXCR3 expression by circulating T cells and intratumoral CXCR3 ligands are independent indicators of a favorable prognosis 21, 22 . Surprisingly, CCR5 and CCR2 did not contribute to T cell trafficking across tumor vessels despite the presence of cognate chemokines in the tumor microenvironment. These findings highlight the disconnect between functional readouts from in vitro chemotaxis assays and in vivo trafficking. Our results corroborate observations that the chemotactic response to soluble chemokine does not reflect the proadhesive signals delivered by immobilized chemokine on two dimensional endothelial surfaces [41] [42] [43] . Collectively, these studies reveal a unique role for CXCR3/CXCR3 ligands in cancer immunotherapy in vivo that could not be predicted from genomic and proteomic profiling of the inflammatory signature in the tumor microenvironment.
Our findings, together with recent reports 23, 24 , suggest that the dependence of effector T cells on G αi protein signaling at the vascular interface is dictated by the inflammatory context, thus having broad implications outside the tumor milieu. Central to these studies was the discrimination of G αi -dependent trafficking mechanisms using PTX which irreversibly uncouples G αi protein signaling from chemokine receptor/ligand binding 19 . Our data establish the requirement for PTX-dependent signaling during the transition of CD8 + effector cells from rolling to firm arrest in tumor vessels as well as in normal vessels in the context of LPS-induced systemic inflammation. This requirement is in line with evidence that CXCR3 contributes to CD8 + T cell localization in inflamed normal skin 19, 44, 45 as well as the prevailing view whereby chemokines trigger a conformational change in LFA-1, resulting in an ~500-fold increased affinity for ICAM-1 that stabilizes intravascular adhesion 19, 46 . Intermediate chemokine receptor requirements were described during DTH responses in which CD8 + effectors bypass G αi protein signaling during the firm adhesion step, and instead rely primarily on CCR2 during transendothelial migration 23 . Cardiac allograft rejection models represent the other end of the spectrum where extravasation of CD8 + effector T cells is completely independent of G αi protein signaling 24 . The reasons for these differential chemokine requirements are unclear, but likely involve variability within the tissue microenvironment rather than T cell behavior since each of these disparate reports used activated OT-I CD8 + effector T cells. One possibility is that differences in downstream TLR signaling following induction of local DTH by injection of complete freund's adjuvant 23 (via TLR2 47 ) or by systemic LPS administration (via TLR4 48 ) account for distinct chemokine receptor requirements in the intravascular space 49 . A key difference between the allograft model and our studies is that G αi -independent trafficking occurs as a consequence of TcR activation by transplant antigens presented by vascular endothelium or nearby DCs 24 . In contrast, results of the current study combined with our previous findings 14 indicate that trafficking of murine T cells or normal donor-derived human CD8 + effectors to tumors or inflamed tissues is not antigen-restricted, which may serve to reinforce T cell dependence on intravascular chemokines.
Observations that CCR2 and CCR5 do not participate during CD8 + effector T cell trafficking into melanoma tumors raise questions about how CCR2 supports monocyte homing in the same intravascular chemokine environment. This could be explained, in part, by the recently discovered post-translational nitration of CCL2 which supports monocyte but not effector T cell chemotaxis in vitro 38 . Nitrated CCL2 is found in the tumor microenvironment of murine and human colon and pancreatic tumors 38 , presumably modified by nitric oxygen species derived from local protumorigenic myeloid cells. Furthermore, global blockade of peroxynitrite enhances T cell infiltration and decreases detectable nitrated CCL2 in murine tumors, although a cause-and-effect relationship for these observations remains to be established 38 . The commercial Ab used to detect intravascular CCL2 in our studies does not appear to recognize nitrated CCL2 in tumor tissues 38 (Dr. Barbara Molon, personal communication), so there may still be a substantial pool of nitrated CCL2 on the intravascular surface which could preferentially support monocyte trafficking. Differential migratory responses of monocytes and T cells to nitrated CCL2 in vitro have been attributed to higher CCR2 surface expression on monocytes 38 , a distinction that we also observed for murine CD115 + inflammatory monocytes and CD8 + effectors.
Evidence that human effector CD8 + T cells expressing high levels of CCR2 or CCR5 failed to utilize these receptors during trafficking to human melanoma tumors suggests that deficient receptor expression cannot fully account for the selective dependence of CD8 + effectors on CXCR3 in vivo. These results indicate that there may be cell-intrinsic properties that impact chemokine receptor activity in vivo, such as variations in the availability of molecules which regulate G αi protein signaling downstream of receptor activation. Strong candidates for cell-specific negative regulation include G protein-coupled receptor kinases (GRK), which phosphorylate the C-terminal intracellular loop of chemokine receptors to prevent the association of heterotrimeric G αβγ complexes 50, 51 , and regulators of G protein signaling (RGS), which accelerate the exchange of GTP on active G α subunits to limit signal duration [50] [51] [52] . Notably, the GRK2 isoform is elevated in activated human T cells compared to monocytes 53, 54 and is implicated in repressing both CCR2 and CCR5 signaling 55, 56 . Similarly, elevated expression of RGS-1 has been reported in activated T cells compared to peritoneal macrophages 57 . Thus, it is likely that the net balance of regulatory molecules for G αi signaling within cells has a substantial impact on the ability of CD8 + effectors to respond to intravascular CCR2 and CCR5 ligands in tumors.
Our data support a scenario whereby CXCR3-dependent delivery of blood-borne T cells at the vascular juncture is a critical step in therapeutic antitumor immunity. Since CXCR3, CCR5, and CCR2 are all associated with overall levels of T cell infiltration and positive outcomes in cancer patients 1, 20, 21 , it is tempting to speculate that signaling through these or other G αi -linked receptors support the antitumor activity of CD8 + T cells within the interstitium via mechanisms independent of extravasation. For example, in vitro studies have shown that CXCR3 and CCR5 enhance T cell activation and proliferation 58, 59 while CCL2 can increase the cytotoxicity of T cells engineered to co-express CCR2 and chimeric antigen receptors 60 . Additionally, ligand engagement of the G αi -coupled leukotriene B4 (LTB4) receptor (BLT) has been linked to increased accumulation of CD8 + T cells and T cellmediated antitumor immunity in murine cervical cancer model 61 . Although not addressed in the current study, CXCR3 on T cells could also function outside tumor tissues by regulating antitumor immunity within lymphoid organs. In this regard, CXCR3 has already been implicated in non-tumor systems in guiding CD4 + or CD8 + T cell positioning near antigenloaded DCs within lymph nodes and the spleen during T cell priming and the generation of effector populations 25, 62 . These observations are highly relevant to preclinical and clinical adoptive T cell transfer therapy in which the efficacy depends on direct cytotoxic functions of effector T cells within tumors as well as seeding of lymphoid organs by memory T cells to perpetuate long-term antitumor immunity 8, 12, 14, 18 .
In summary, this report identifies the interface between CXCR3 on effector T cells and chemokine ligands within tumor vessels as a critical checkpoint dictating the efficacy of T cell-based cancer immunotherapy. The experimental strategy used here to interrogate the homing properties of large numbers of transferred T cells is analogous to clinical adoptive transfer protocols where the goal is to massively expand the tumor-specific T cell pool. As an example, recent studies have shown that it is technically feasible to transfer > 120 billion tumor-reactive T cells in a patient in a bolus injection 63 . Given our observations that CXCR3 is also required for intratumoral localization of endogenous CD8 + T cells, it is likely that conclusions regarding biased CXCR3 usage are also relevant to other immunotherapies in which a lower frequency of tumor-reactive T cells might be generated. Similar CXCR3 requirements for homing of CD8 + effectors may also be operative in other orthotopic murine tumors such as the PyMT breast tumor model, which exhibits more aggressive growth after implantation in Cxcr3 −/− hosts because of M2 macrophage polarization 64 .
These observations provide guidance for which chemokine receptor/chemokine pair could be exploited clinically to improve antitumor immunity. Our results, together with other published studies, demonstrate that there is universally high CXCR3 expression on ex vivo activated human T cells either from normal donors or cancer patients 20, 37 . Thus, inadequate expression of CXCR3 does not appear to be an obstacle to adoptive T cell immunotherapy. In contrast, the tumor microenvironment is highly variable with respect to CXCR3 ligand expression 1, 20, 21, 37 . This raises the possibility of using therapeutic strategies to boost CXCR3 ligands in the tumor locale which could be shuttled out onto the endothelial surface through the process of transcytosis 65, 66 . Several approaches being studied clinically to promote an antitumorigenic inflammatory gene signature such as administration of TLR ligands (e.g., CpG or poly I:C), or IFN-α have been shown in preclinical studies to induce production of CXCR3 ligands by intratumoral stromal cells (fibroblasts, monocytes, or CD45 + leukocytes) 9, 15, 67 . Commonly used chemotherapeutic agents such as cisplatin and temozolomide similarly boost tumor cell expression of CXCR3 ligands in preclinical melanoma models, paralleling the increases in CXCL9 and CXCL10 gene expression detected in melanoma patient tumors after treatment with dacarbazine 68 . Moreover, intratumoral injection of recombinant CXCL10 or adenovirus encoding CXCL10 reportedly contributes to CD8 + T cell infiltration and tumor rejection in murine tumors 69, 70 . Based on our current findings, we would predict that chemokine-targeting strategies further offers promise in an adjuvant setting with adoptive T cell transfer therapy, cancer vaccines, or checkpoint blockade inhibitors that rescue CD8 + T cell function by disrupting CTLA-4 and PD-1/PD-L1-mediated immune-suppressive networks 8, 10, 11, 13 . It is noteworthy, in this regard, that elevated CXCL9 expression in patient melanoma specimens correlates with response to PD-L1 blockade therapy 13 . Tumor models B16-OVA cells and parental B16 were cultured in complete media (RPMI 1640 supplemented with 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, 50 μg/ml streptomycin, and 50 μM β-mercaptoethanol [Invitrogen]). M537 and M888 cells were cultured in complete media lacking β-mercaptoethanol 20, 35, 36 . EL4 and EG7 cells were cultured in complete media supplemented with 1 mM sodium pyruvate, MEM non-essential amino acids, 25 mM HEPES (Invitrogen); media for EG7 cells contained 40 μg/mL G418 sulfate (LifeTechnologies). Tumor cells (10 6 ) were injected subcutaneously in the flank of C57BL/6 mice or SCID mice as previously described 14, 20 and used for experimental analysis when tumor volume reached ~400-500 mm 3 (~10-14 days or 6-8 weeks postimplantation for murine and human melanoma, respectively) unless otherwise indicated.
Methods
Animals
T cell activation ex vivo or in vivo
Pooled murine splenocyte/lymph node populations (2 × 10 6 cells/ml) were activated for 2 days in 24-well plates (Corning) coated with anti-mouse CD3 Ab (2.5 μg/ml; Cat # 550275 clone 145-2C11; BD Biosciences) in complete media (including MEM non-essential amino acids, 20 mM HEPES, 1.5 mM sodium pyruvate); then diluted to 2 × 10 5 cells/ml, and expanded for 3 days with recombinant human IL-2 (12.5 ng/ml; Peprotech). Human PBMC were isolated from anonymous normal donor buffy-coats obtained from the Roswell Park blood donor center by centrifugation on a Ficoll-Hypaque gradient, washed with HBSS, and suspended in complete media (with 100 μg/ml streptomycin and without β-mercaptoethanol). PBMC were activated for 2 days with anti-human CD3 Ab (2 μg/ml; Cat# 16-0037-81 OKT3; eBiosciences) and anti-CD28 Ab, then expanded for 5 days with recombinant human IL-2 (300 IU/ml; Novartis). All Ab and cytokines were azide and endotoxin-free. DC vaccination was performed to activate CD8 + CD44 + T cells in vivo. Mouse bone marrow-derived DCs were generated by culturing bone marrow cells for 8 days in media used for murine T cell activation, supplemented with murine GM-CSF (~20 ng/ml; provided by Dr. Kelvin Lee, Roswell Park Cancer Institute). DCs were matured by LPS treatment (0.5 μg/ml) overnight, then pulsed with 5 μM SIINFEKL peptide (InvivoGen), and 3 × 10 6 DCs were injected into the hind footpad; T cells were recovered from draining nodes (popliteal, inguinal) after 7 days. As an alternative method for in vivo activation, T cells were analyzed in draining nodes (inguinal) 7 days after B16-OVA tumor implantation.
Treatment with STT, LPS, or cytokine-neutralizing reagents
Mice were treated with systemic thermal therapy (STT; core temperature of 39.5 ± 0.5°C, 6 h) and allowed to return to baseline temperature prior to homing studies as described 14, 27 . LPS (1 mg/kg; Sigma) was injected i.p. 6 h prior to trafficking studies 14 . Neutralizing polyclonal anti-CXCL9 or anti-CXCL10 Ab 30 (100 μg/mouse) or polyclonal isotype IgG control (cat# BE0091 100 μg/ mouse; BioXCell) were injected i.p. 3 h prior to competitive homing studies. Murine activated CD8 + T cells were pretreated with pertussis toxin (100 ng/ml, 2.5 h; Sigma), or anti-mouse CXCR3 blocking Ab (cat# 126526 100 μg/mL, 1h; Biolegend). Human activated T cells were pretreated with pertussis toxin, human CXCR3 functional blocking Ab (cat# LS-C6283-500 40 μg/ml, 30 min; LifeSpan BioSciences, Inc 39 ), or human recombinant CXCL10 (500nM, 30 m; Peprotech) to desensitize CXCR3 40 .
Quantification of tissue and intravascular chemokines
Soluble extracts from tumor or normal skin were prepared by dissociating tissue by Medimachine (BD Biosciences) in the presence of protease inhibitors (CalBiochem). Chemokines were measured by ELISA (R&D Systems and Antigenix) or Luminex (Procarta) and normalized to total protein concentrations determined by Bradford analysis (Bio-Rad) 14 . Normal skin samples were from mice that received a s.c. injection of 100 μl sterile PBS 12 day prior to tissue harvest to mimic any needle-derived inflammation at the injection site. Intravascular chemokines were detected by adapting methodology used to identify intravascular adhesion molecules in LN 28 . Briefly, yellow-green fluorescent sulfate microspheres (Ex/Em 505/515, 1.0 μm diameter, Life Technologies) were labeled with 10 μg/mL of Ab specific for mouse chemokines including anti-CXCL10 (cat# MAB466-500 clone 134013), anti-CXCL9 (cat# AF392 affinity-purified polyclonal Ab), anti-CCL5 (cat# MAB478 clone 53405), anti-CCL2 (cat# BAF479 biotinylated affinity purified polyclonal goat Ab), or isotype-matched control Abs (R&D Systems) 28 and injected i.v. into tumorbearing mice. After 1 h, tumor and pancreas were frozen in OCT (Sakura Finetek), and then counterstained using anti-mouse CD31 Ab (cat# 550274 clone MEC 13.3, 20 μg/ml; BD Biosciences) followed by an AMCA fluorochrome-conjugated goat anti-rat secondary Ab (cat# 112-155-003 1:50 Jackson ImmunoResearch). For consistency, fields containing a minimum of 1 fluorescent bead were imaged by observers blinded to sample identity, and the number of fluorescently beads associated with CD31 + vessels was quantified in ≥10 fields (unit area per field, 0.34 mm 2 ) using Image J software (http://rsb.info.nih.gov/ij) as described 14 .
Flow cytometry
Multiparameter flow cytometric analysis of murine immune cell phenotype was performed by staining with the following mAb: anti-CD44 (Cat# 561859 clone IM7, FITC, 1:50), antiCD11a (cat# 553120/cat# 558191 clone 2D7, FITC/PE, 1:100), anti-CD8a (cat# 553036 clone 53-6.7, PerCP, 1:100; cat# 552877 clone 53-6.7, Pe-Cy7, 1:500), anti-CD11b (cat# 561098 clone 1M/70, PE-Cy7 1:100), anti-Ly6C (cat# 560595 clone AL-21, APC, 1:100), anti-CCR5 (cat# 559923 clone C34-3448, PE, 1:20), anti-CD45.1 (cat# 560578 clone A20, PE-Cy7, 1:100), anti-CD45. 
Chemotaxis assays
Chemotaxis of murine and human effector T cells was assayed in 24 well plates (5 μM pore size transwell insert with polycarbonate membranes; Corning). Media alone (RPMI1640 + 1%BSA) or media containing recombinant chemokines (Peprotech) was placed at the bottom of triplicate wells. Murine T cell migration was assessed at 10 nM murine CXCL10, 1 nM murine CCL2, and 10 nM murine CCL5; human T cell chemotaxis was determined at 100 ng/mL recombinant human or murine chemokine 20 unless otherwise indicated. 5 × 10 5 cells were fluorescently labeled with CFSE or CTO, placed on the transwell insert, and incubated at 37°C for 3 h. Cells in the bottom chamber were enumerated by flow cytometry using Flow Count Beads (Beckman Coulter). Spontaneous migration was subtracted from all conditions, and data are reported either as absolute number of cells migrated or as migration relative to WT T cells.
In vivo homing assays
Competitive short-term (1 h) homing assays were performed by co-mixing (1:1 ratio) 2.5 × 10 7 murine CD8 + T cells labeled with 5 -(and 6) -carboxyfluorescein diacetate succinimidyl ester (CFSE) with equal numbers of murine CD8 + T cells labeled with 5 -(and 6) -(4 -chloromethyl) benzoyl) amino) tetramethylrhodamine (CellTracker Orange, Invitrogen Life Technologies) prior to i.v. adoptive transfer. In homing studies using ex vivo activated human T cells, ~1.5 × 10 7 of CFSE-or CTO-labeled cells were mixed at equivalent numbers prior to injection into tumor-bearing mice. Tumor and spleen were collected 1 h later and mechanically dissociated by Medimachine (BD Biosciences) or passed through a 70 μm nylon cell strainer (BD Biosciences). Ratios of fluorescent adoptively-transferred cells were determined by flow cytometry, and total cell numbers were assessed using Flow Count Beads (Beckman Coulter) 14 . In selected experiments intratumoral infiltration by OT-I cells was monitored using tracking dyes (CellVue Claret, Sigma Aldrich) or by congenic mismatch (CD45.1 + OT-I→CD45.2 + host) up to 3 weeks after transfer.
Quantification of extravasation by transferred CD8 + T cells
After short-term in vivo homing assays, organs were harvested, embedded in optimum cutting temperature compound (OCT, Sakura Finetek) and snap-frozen as previously described 14 . Tissue cryosections (9 μm) were incubated with the primary Ab specific for murine CD31 (cat# 550274 clone MEC 13.3, 20 μg/ml; BD Biosciences) followed by an AMCA fluorochrome-conjugated goat anti-rat secondary Ab (cat# 112-155-003, 1:50; Jackson ImmunoResearch) and imaged using a fluorescence microscope (Olympus Optical) and a SPOT RT camera (Diagnostic Instruments). In experiments in which the location of homed cells was determined (i.e., extravasated vs vessel-associated), all T cells not in contact with CD31 + endothelial cells were designated as extravasated. For consistency, fields containing a minimum of 1 fluorescently-labeled cell were imaged by observers blinded to sample identity, and labeled cells were quantified in ≥ 10 fields (unit area per field, 0.34 mm 2 ).
Inflammatory monocyte isolation and short-term homing
Tibias and femurs from either WT C57BL/6 or Ccr2 −/− mice were removed sterilely, and bone marrow was flushed with sterile PBS. RBC were lysed with ACK lysing buffer (Gibco) and inflammatory monocytes were isolated on an AutoMacs machine using positive selection with CD115 microbeads (Miltenyi). WT CD115 + cells were labeled with CTO and Ccr2 −/− CD115 + cells were labeled with CFSE, mixed at a 1:1 ratio, and adoptively transferred into B16-OVA-bearing mice. After 2 h, tumor and splenic tissues were analyzed for flow cytometry.
Intravital microscopy
Live imaging of tumor or normal tissues was performed as described 14, 27 . Briefly, dorsal skin-flap single-sided window chambers (Research Instruments Inc.) were surgically implanted in C57BL/6 mice and 1 × 10 5 B16-OVA cells were injected into the center of the chamber. Mice were housed in a 30°C environmental chamber to promote wound-healing and the adhesive qualities of the tumor microvasculature was evaluated ~14-21 days postimplantation. In the indicated studies, T cell interactions were also examined in non-tumor inflamed skin vessels. Following treatment of the mice with STT or LPS, mice were anesthetized (1 mg/ml xylazine and 10 mg/ml ketamine; 10 ml/kg, i.p.) and 5-10 × 10 7 calcein-labeled effector WT or Cxcr3 −/− OT-I T cells were injected via tail vein over the 30 min observation period. An epi-illumination intravital microscope with a custom stage equipped with a warming pad and vibration dampening system (Spectra Services) was used to visualize the interactions between the circulating T cells and the microvasculature. Images were captured with an EB charge-coupled device camera (Hamamatsu Photonics) and recorded with a digital videocassette recorder (DSR-11; Sony) and quantified by observers blinded to treatment conditions. T cell interactions were quantified in unbranched vascular segments 100 μm in length with a diameter between 5-40 μm. The rolling fraction was the percentage of total cells that interacted per microvessel; sticking fraction was the percentage of rolling cells that subsequently adhered for ≥30 s 14, 27 .
In vitro and in vivo cytotoxicity assays
OVA-expressing target cells (either splenocytes pulsed with 5 μg/mL SIINFEKL peptide [InvivoGen], B16-OVA cells, or EG7 cells) were labeled with CFSE and mixed at a 1:1 ratio with CTO-labeled non-antigen-expressing cells (i.e., non-pulsed splenocytes, B16 cells, or EL4 cells, respectively) and incubated in triplicate in the absence of effector T cells, or in the presence of a 15-fold excess of effector WT OT-I or Cxcr3 −/− OT-I T cells. After 24 h, live cells were analyzed by flow cytometry. For in vivo cytotoxicity assays, OVApulsed and non-pulsed splenocytes were mixed at a 1:1 ratio (~4-5 ×10 6 of each population/ mouse) and transferred i.v. into naïve mice in which 3 × 10 7 WT or Cxcr3 −/− effector OT-I T cells had been injected 3 h previously. 24 h later, spleens were harvested, lysed, and live cells were analyzed by flow cytometry. The proportion of fluorescently-labeled cells was plotted as CFSE + and CFSE − cells on histograms, and the % specific cytotoxicity was determined by the formula [1-(% CFSE − cells/% CFSE + cells)] × 100%.
Tumor growth studies
WT or Cxcr3 −/− OT-I effector T cells (5 × 10 6 /mouse) were transferred i.v. into B16-OVAbearing mice. Experimental endpoints were reached when tumors exceeded 20 mm diameter or mice became moribund. Tumor volumes were calculated by determining the length of short (l) and long (L) diameters (volume = l 2 × L/2) as described 14 .
Statistical analysis
All data shown are the mean ± s.e.m. and group differences were evaluated by unpaired twotailed Student's t-test as described unless otherwise specified. Statistical significance of tumor growth was determined by two-way ANOVA for repeated measures. Survival data were analyzed using Kaplan-Meier log rank tests. P-values < 0.05 were considered significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. Concentration of human and murine chemokines in tumor extracts from 2 human melanoma xenografts (M537 and M888) was determined by Luminex and ELISA, respectively. Data (mean ± s.e.m.) are from 4 independent experiments (n ≥4 mice per group) for human chemokines and from ≥2 independent experiments (n ≥3 mice per group) for murine chemokines. * P < 0.05; ** P < 0.006, M537 versus M888 tumors. (c) Left, schematic for short-term (1 h) competitive homing studies. The groups used for adoptive cell transfer (ACT) included untreated (Untx) human effector T cells from donor 1 or donor 2 that were Mikucki et al. Page 29 comixed at a 1:1 ratio with untreated cells, PTX-pretreated cells, α-CXCR3 Ab-pretreated cells, or cells where CXCR3 was desensitized by exposure to recombinant CXCL10 prior to transfer into mice (CXCR3 dsn). Right, ratio of adoptively transferred T cells relative to untreated cells in tumors of M537 or M888 tumor-bearing SCID mice following short-term competitive homing assays is shown. PTX, pertussis toxin; α-CXCR3, CXCR3 blocking Ab. Data (mean ± s.e.m.) are from ≥2 independent experiments (n = 2 mice per group). * P < 0.02; ns, not significant. (b-c) Data analyzed by unpaired two-tailed Student's t-test.
